Cargando…
Diagnostic biomolecules and combination therapy for pre-eclampsia
Pre-eclampsia (PE), associated with placental malperfusion, is the primary reason for maternal and perinatal mortality and morbidity that can cause vascular endothelial injury and multi-organ injury. Despite considerable research efforts, no pharmaceutical has been shown to stop disease progression....
Autores principales: | Qi, Jingqi, Wu, Bingbing, Chen, Xiuying, Wei, Wei, Yao, Xudong |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9446775/ https://www.ncbi.nlm.nih.gov/pubmed/36068569 http://dx.doi.org/10.1186/s12958-022-01003-3 |
Ejemplares similares
-
Combined Screening for Early Detection of Pre-Eclampsia
por: Park, Hee Jin, et al.
Publicado: (2015) -
Pre-Eclampsia and Eclampsia: An Update on the Pharmacological Treatment Applied in Portugal †
por: Peres, Gonçalo Miguel, et al.
Publicado: (2018) -
The Relationship between Obesity and Pre-Eclampsia: Incidental Risks and Identification of Potential Biomarkers for Pre-Eclampsia
por: Abraham, Talitha, et al.
Publicado: (2022) -
Clinical pharmacokinetic properties of magnesium sulphate in women with pre‐eclampsia and eclampsia
por: Okusanya, BO, et al.
Publicado: (2015) -
Policy review on the management of pre-eclampsia and eclampsia by community health workers in Mozambique
por: Macuácua, Salésio, et al.
Publicado: (2019)